Sabrina Segreto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sabrina Segreto has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Marco Salvatore
IRCCS Synlab SDN, 80143 Naples, Italy
5 shared publications - Pier Paolo Mainenti
Institute of Biostructures and Bioimaging of the National Council of Research (CNR), Naples, Italy
5 shared publications - Leonardo Pace
Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy
4 shared publications - Barbara Salvatore
Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy
3 shared publications - Rosa Fonti
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
3 shared publications - Silvana Del Vecchio
Department of Advanced Biomedical Sciences, University “Federico II”, Naples, Italy
3 shared publications
Latest Publications
- 11 January 2016
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 30 (3) , 234-241
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma
The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography (111In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC).
- 11 January 2016
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 30 (3) , 234-241
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma
The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography (111In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC).
- 1 November 2015
- Published by Elsevier in Academic Radiology
- Vol. 22 (11) , 1419-1426
Balancing Radiation and Contrast Media Dose in Single-Pass Abdominal Multidetector CT
- 1 November 2015
- Published by Elsevier in Academic Radiology
- Vol. 22 (11) , 1419-1426
Balancing Radiation and Contrast Media Dose in Single-Pass Abdominal Multidetector CT
- 28 October 2015
- Published by Elsevier in European Journal of Radiology
- Vol. 85 (1) , 113-124
Diffusion volume (DV) measurement in endometrial and cervical cancer: A new MRI parameter in the evaluation of the tumor grading and the risk classification
- 28 October 2015
- Published by Elsevier in European Journal of Radiology
- Vol. 85 (1) , 113-124
Diffusion volume (DV) measurement in endometrial and cervical cancer: A new MRI parameter in the evaluation of the tumor grading and the risk classification
- 27 May 2013
- Published by Springer Nature in La radiologia medica
- Vol. 118 (7) , 1109-1118
Prevalence of extramammary findings on breast MRI: a large retrospective single-centre study
Purpose This study sought to determine the prevalence of extramammary findings on magnetic resonance (MR) imaging of the breast. Materials and methods We retrospectively reviewed the data sets of 828 consecutive patients (F/M; 821/7; mean age, 50±11 years) who underwent breast MR imaging. The most common clinical indication was assessment of lesion extent in patients with known breast tumour (n=380, 46%), characterisation of equivocal findings at conventional imaging (n=331, 40%), evaluation of women at high risk for breast cancer (n=43, 5%) and following breast augmentation therapy (n=74, 9%). Results Collateral findings were found in 282/828 (34%) patients. In those 282 patients, 480 incidental lesions were detected. The most common localisation was the liver (231/480; 48%). Of the 480 collateral findings, 66 (14% in 38 patients) were classified as significant and deserving further investigation. These comprised 26 metastatic bony lesions, 15 mediastinal/axillary lymph nodes, six metastatic lung lesions, five metastatic liver lesions, four pneumonitis, two aneurysms of the ascending aorta, two adrenal adenomas, one neurofibroma of the back, one multiple myeloma, one mediastinal lymphoma, one sternal amyloidosis, one left ventricular dilatation and one trapezium lipoma. Conclusions There is a high prevalence of extramammary findings on breast MR imaging. Evaluation of the examination should focus not only on the breast fields but also consider extramammary findings to avoid inappropriate management and possible legal issues.
- 27 May 2013
- Published by Springer Nature in La radiologia medica
- Vol. 118 (7) , 1109-1118
Prevalence of extramammary findings on breast MRI: a large retrospective single-centre study
Purpose This study sought to determine the prevalence of extramammary findings on magnetic resonance (MR) imaging of the breast. Materials and methods We retrospectively reviewed the data sets of 828 consecutive patients (F/M; 821/7; mean age, 50±11 years) who underwent breast MR imaging. The most common clinical indication was assessment of lesion extent in patients with known breast tumour (n=380, 46%), characterisation of equivocal findings at conventional imaging (n=331, 40%), evaluation of women at high risk for breast cancer (n=43, 5%) and following breast augmentation therapy (n=74, 9%). Results Collateral findings were found in 282/828 (34%) patients. In those 282 patients, 480 incidental lesions were detected. The most common localisation was the liver (231/480; 48%). Of the 480 collateral findings, 66 (14% in 38 patients) were classified as significant and deserving further investigation. These comprised 26 metastatic bony lesions, 15 mediastinal/axillary lymph nodes, six metastatic lung lesions, five metastatic liver lesions, four pneumonitis, two aneurysms of the ascending aorta, two adrenal adenomas, one neurofibroma of the back, one multiple myeloma, one mediastinal lymphoma, one sternal amyloidosis, one left ventricular dilatation and one trapezium lipoma. Conclusions There is a high prevalence of extramammary findings on breast MR imaging. Evaluation of the examination should focus not only on the breast fields but also consider extramammary findings to avoid inappropriate management and possible legal issues.
- 1 September 2012
- Published by Elsevier in Clinical Imaging
- Vol. 36 (5) , 559-567
Tomographic imaging of the spleen: the role of morphological and metabolic features in differentiating benign from malignant diseases
- 1 September 2012
- Published by Elsevier in Clinical Imaging
- Vol. 36 (5) , 559-567
Tomographic imaging of the spleen: the role of morphological and metabolic features in differentiating benign from malignant diseases
- 8 June 2011
- Published by Springer Nature in Emergency Radiology
- Vol. 18 (6) , 483-486
CT findings in a mixed-type acute gastric volvulus
- 8 June 2011
- Published by Springer Nature in Emergency Radiology
- Vol. 18 (6) , 483-486
CT findings in a mixed-type acute gastric volvulus
- Open Access
- 1 January 2010
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (20) , 2566-70
Intestinal amyloidosis: Two cases with different patterns of clinical and imaging presentation
The involvement of the small bowel in systemic forms of amyloidosis may be diffuse or very rarely focal. Some cases of focal amyloidomas of the duodenum and jejunum without extraintestinal manifestations have been reported. The focal amyloidomas consisted of extensive amyloid infiltration of the entire intestinal wall thickness. Radiological barium studies, ultrasound and computed tomography (CT) patterns of diffuse small bowel amyloidosis have been described: the signs are non-specific and may include small-bowel dilatation, symmetric bowel wall thickening, mesenteric infiltration, and mesenteric adenopathy. No data are available about the positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) patterns of intestinal amyloidosis. We report two cases of small bowel amyloidosis: the former characterized by focal deposition of amyloid proteins exclusively within blood vessel walls of the terminal ileum, the latter characterized by diffuse intestinal involvement observed on MRI and PET/CT studies.
- 1 January 2010
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (20) , 2566-70
Open AccessIntestinal amyloidosis: Two cases with different patterns of clinical and imaging presentation
The involvement of the small bowel in systemic forms of amyloidosis may be diffuse or very rarely focal. Some cases of focal amyloidomas of the duodenum and jejunum without extraintestinal manifestations have been reported. The focal amyloidomas consisted of extensive amyloid infiltration of the entire intestinal wall thickness. Radiological barium studies, ultrasound and computed tomography (CT) patterns of diffuse small bowel amyloidosis have been described: the signs are non-specific and may include small-bowel dilatation, symmetric bowel wall thickening, mesenteric infiltration, and mesenteric adenopathy. No data are available about the positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) patterns of intestinal amyloidosis. We report two cases of small bowel amyloidosis: the former characterized by focal deposition of amyloid proteins exclusively within blood vessel walls of the terminal ileum, the latter characterized by diffuse intestinal involvement observed on MRI and PET/CT studies.
- 16 January 2008
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (2) , 195-200
18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
New imaging techniques have been introduced to assess the extent and severity of disease in multiple myeloma (MM) patients. The aim of our study was to compare newer imaging modalities-such as (18)F-FDG PET/CT, (99m)Tc-methoxyisobutylisonitrile ((99m)Tc-MIBI) scintigraphy, and MRI-to assess their relative contribution in the evaluation of MM patients at diagnosis. Thirty-three newly diagnosed patients with MM were prospectively studied. Diagnosis and staging were made according to standard criteria. All patients underwent whole-body (18)F-FDG PET/CT, whole-body (99m)Tc-MIBI, and MRI of the spine and pelvis within 10 d, and imaging findings were compared. (18)F-FDG PET/CT was positive in 32 patients (16 focal uptake, 3 diffuse uptake, 13 focal and diffuse uptake), (99m)Tc-MIBI was positive in 30 patients (6 focal, 11 diffuse, 13 focal and diffuse uptake), and MRI of the spine and pelvis was positive in 27 patients (6 focal, 13 diffuse, 8 focal and diffuse uptake). (18)F-FDG PET/CT showed a total of 196 focal lesions (178 in bones and 18 in soft tissues), of which 121 were in districts other than the spine and pelvis, whereas (99m)Tc-MIBI visualized 63 focal lesions (60 in bones and 3 in soft tissues), of which 53 were in districts other than the spine and pelvis. In the spinal and pelvic regions, (18)F-FDG PET/CT detected 75 focal lesions (35 in spine and 40 in pelvis), (99m)Tc-MIBI visualized 10 focal lesions (1 in spine and 9 in pelvis), and MRI detected 51 focal lesions (40 in spine and 11 in pelvis). In whole-body analysis, (18)F-FDG PET/CT performed better than (99m)Tc-MIBI in the detection of focal lesions, whereas (99m)Tc-MIBI was superior in the visualization of diffuse disease. In the spine and pelvis, MRI was comparable to (18)F-FDG PET/CT and (99m)Tc-MIBI in the detection of focal and diffuse disease, respectively. Because myelomatous lesions may often occur out of spinal and pelvic regions, MRI should be reserved to the evaluation of bone marrow involvement of these districts, whereas (18)F-FDG PET/CT can significantly contribute to an accurate whole-body evaluation of MM patients. Finally, whole-body (99m)Tc-MIBI, despite its limited capacity in detecting focal lesions, may be an alternative option when a PET facility is not available.
- 16 January 2008
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (2) , 195-200
18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
New imaging techniques have been introduced to assess the extent and severity of disease in multiple myeloma (MM) patients. The aim of our study was to compare newer imaging modalities-such as (18)F-FDG PET/CT, (99m)Tc-methoxyisobutylisonitrile ((99m)Tc-MIBI) scintigraphy, and MRI-to assess their relative contribution in the evaluation of MM patients at diagnosis. Thirty-three newly diagnosed patients with MM were prospectively studied. Diagnosis and staging were made according to standard criteria. All patients underwent whole-body (18)F-FDG PET/CT, whole-body (99m)Tc-MIBI, and MRI of the spine and pelvis within 10 d, and imaging findings were compared. (18)F-FDG PET/CT was positive in 32 patients (16 focal uptake, 3 diffuse uptake, 13 focal and diffuse uptake), (99m)Tc-MIBI was positive in 30 patients (6 focal, 11 diffuse, 13 focal and diffuse uptake), and MRI of the spine and pelvis was positive in 27 patients (6 focal, 13 diffuse, 8 focal and diffuse uptake). (18)F-FDG PET/CT showed a total of 196 focal lesions (178 in bones and 18 in soft tissues), of which 121 were in districts other than the spine and pelvis, whereas (99m)Tc-MIBI visualized 63 focal lesions (60 in bones and 3 in soft tissues), of which 53 were in districts other than the spine and pelvis. In the spinal and pelvic regions, (18)F-FDG PET/CT detected 75 focal lesions (35 in spine and 40 in pelvis), (99m)Tc-MIBI visualized 10 focal lesions (1 in spine and 9 in pelvis), and MRI detected 51 focal lesions (40 in spine and 11 in pelvis). In whole-body analysis, (18)F-FDG PET/CT performed better than (99m)Tc-MIBI in the detection of focal lesions, whereas (99m)Tc-MIBI was superior in the visualization of diffuse disease. In the spine and pelvis, MRI was comparable to (18)F-FDG PET/CT and (99m)Tc-MIBI in the detection of focal and diffuse disease, respectively. Because myelomatous lesions may often occur out of spinal and pelvic regions, MRI should be reserved to the evaluation of bone marrow involvement of these districts, whereas (18)F-FDG PET/CT can significantly contribute to an accurate whole-body evaluation of MM patients. Finally, whole-body (99m)Tc-MIBI, despite its limited capacity in detecting focal lesions, may be an alternative option when a PET facility is not available.
- 7 February 2007
- Published by Springer Nature in Annals of Hematology
- Vol. 86 (6) , 415-423
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis
Osteonecrosis of the maxillary or mandibular bone is an infrequent but often severe event occurring in patients who undergo prolonged treatment with bisphosphonates. Histology is in some cases mandatory to differentiate it from neoplastic osteolysis, but a biopsy can further contribute to bone damage. Functional imaging obtained by a tracer that shows oncotropic properties, such as Tc99m-sestamibi, in comparison to a non-tumor-specific substance such as FDG-PET, can support the differential diagnosis, thus avoiding invasive procedures. Four patients affected by multiple myeloma and jaw osteonecrosis were prospectively evaluated by sestamibi and FDG-PET scans. Local diagnosis was performed by clinical, radiological and, in some cases, histological evaluations. Each patient was studied by Tc99m-sestamibi, performed by planar anterior and posterior whole-body scans and SPECT of the head and neck, and by PET/CT. Two nuclear medicine physicians, unaware of the final diagnosis, reviewed the images. No sestamibi uptake was evident in the four patients with jaw osteonecrosis, while FDG-PET/CT showed focal uptake in all of them. Our study suggests that the combined use of sestamibi scintigraphy and FDG-PET/CT could support the clinical diagnosis of oral osteonecrosis avoiding the risks of a surgical biopsy. Studies on higher number of patients are necessary to validate these preliminary observations.
- 7 February 2007
- Published by Springer Nature in Annals of Hematology
- Vol. 86 (6) , 415-423
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis
Osteonecrosis of the maxillary or mandibular bone is an infrequent but often severe event occurring in patients who undergo prolonged treatment with bisphosphonates. Histology is in some cases mandatory to differentiate it from neoplastic osteolysis, but a biopsy can further contribute to bone damage. Functional imaging obtained by a tracer that shows oncotropic properties, such as Tc99m-sestamibi, in comparison to a non-tumor-specific substance such as FDG-PET, can support the differential diagnosis, thus avoiding invasive procedures. Four patients affected by multiple myeloma and jaw osteonecrosis were prospectively evaluated by sestamibi and FDG-PET scans. Local diagnosis was performed by clinical, radiological and, in some cases, histological evaluations. Each patient was studied by Tc99m-sestamibi, performed by planar anterior and posterior whole-body scans and SPECT of the head and neck, and by PET/CT. Two nuclear medicine physicians, unaware of the final diagnosis, reviewed the images. No sestamibi uptake was evident in the four patients with jaw osteonecrosis, while FDG-PET/CT showed focal uptake in all of them. Our study suggests that the combined use of sestamibi scintigraphy and FDG-PET/CT could support the clinical diagnosis of oral osteonecrosis avoiding the risks of a surgical biopsy. Studies on higher number of patients are necessary to validate these preliminary observations.